Sulodexide is an orally administered combination of glycosaminoglycans, consisting of low molecular weight heparin (80%) and dermatan sulfate (20%). It demonstrates antithrombotic properties by interacting with antithrombin III (AT III) and heparin cofactor II (HC II), and by inhibiting thrombin formation. Additionally, sulodexide enhances profibrinolytic activity by releasing tissue plasminogen activator (tPA). It also offers endothelial protection, possesses anti-inflammatory effects, and alleviates chronic venous disease .